Session Description
Epidemiological evidence highlights strong links between Metabolic-Associated Steatotic Liver Disease (MASLD), obesity, insulin resistance, and Type 2 Diabetes Mellitus (T2DM). Endocrinologists face challenges in screening and managing this liver complication, which is increasingly recognized as a key component of metabolic syndrome. Effective care development for MASLD requires collaborative efforts between hepatologists and endocrinologists to establish clear guidelines and protocols. This session will explore emerging pharmacological treatments, including incretin-based therapies, FGF21 analogues, and the panPPAR agonist lanifibranor, targeting both MASLD and T2DM-related liver fibrosis. We will also discuss the first FDA-approved treatment targeting the thyroid hormone receptor to promote anti-fibrotic effects without altering insulin resistance. Join us for a clinical update on screening strategies and the latest treatment options for endocrinologists managing MASLD in patients with metabolic disorders.